Orca Bios BLA for Hematologic Malignancy Cell Therapy Orca-T Accepted by FDA With Priority Review October 7, 2025 Orca Bios BLA for Orca-T, an investigational allogeneic cell therapy product intended to treat various hematologic malignancies, including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndromes (MDS), has been accepted by the FDA with priority review
The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-a review
Our Combo Lipo Skinny/B6/B12 injections in Gilbert, AZ, at LiveWellMD, are the perfect all-in-one solution to help you feel your best fast
Primary Clinical Indications Peripheral Neuropathy: Effectively treats nerve damage caused by diabetes or chronic illness
9 Another study supporting these findings also associated GLP-1 RA treatments with a 46% higher risk of gallstones compared to placebo
EGR-1 and NAB2 are transcription factors involved in regulating cell growth, migration, and angiogenesis, indicating a broader influence on gene expression critical for tissue repair